The Supreme Court’s “Skinny Label” Showdown: What Hikma v. Amarin Means for Generic Drug Companies
On April 29, the Supreme Court will hear argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., a case that may determine whether the Section viii “skinny label” pathway remains viable for generic drug manufacturers. At issue is whether a generic company that fully carves out a patented indication from its label can nevertheless […]